Overview

Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza

Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This Phase 1/2 protocol is designed to collect safety, tolerability and pharmacokinetic data of two doses of Laninamivir Octanoate in children and adolescents. The protocol will also explore virology and efficacy endpoints.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Biota Scientific Management Pty Ltd
Collaborator:
Department of Health and Human Services
Treatments:
Laninamivir
Zanamivir